Treatment News : AbbVie Files for FDA Approval of '3D' Hepatitis C Regimen

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » April 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


April 22, 2014

AbbVie Files for FDA Approval of '3D' Hepatitis C Regimen

On April 22, AbbVie submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its so-called “3D” combination regimen of antivirals to treat adults with genotype 1 of hepatitis C virus (HCV). Supporting the application are six Phase III studies of the treatment in more than 2,300 people around the world—the largest such research program to date in the fast-evolving and highly competitive field of hep C research and development.

The 3D regimen consists of the fixed-dose combination of the protease inhibitor ABT-450 and ritonavir co-formulated with the NS5A inhibitor ombitasvir (ABT-267), as well the non-nucleoside polymerase inhibitor dasabuvir (ABT-333), with or without ribavirin.

In May, the FDA gave the regimen a Breakthrough Therapy Designation, giving it an expedited review process because it may substantially improve upon currently available treatment options.

“This NDA submission is a significant advancement for AbbVie’s HCV development program,” Scott Brun, MD, vice president of pharmaceutical development at AbbVie, said in a release. “Based on the robust data that have been generated in our international Phase III HCV program, we believe our all-oral, interferon-free regimen holds the potential to be a promising new therapy for patients living with this chronic infection.”

With this application, AbbVie raises the stakes in the race to develop blockbuster therapies to treat hep C and tap into potential billions of dollars in sales. On February 10, Gilead filed for approval of the once-daily fixed-dose combination tablet of ledipasvir and the already-approved Sovaldi (sofosbuvir) to treat genotype 1 of hep C. Word on the FDA’s decision about that combination therapy is expected October 10. On April 7, Bristol-Myers Squibb filed for approval of daclatasvir and asunaprevir in combination to treat genotype 1b and for daclatasvir to be used with other hep C antivirals to treat various genotypes.

Thus, the year’s end is likely to yield highly dramatic changes in the treatment options for people living with the virus, as well as a potential price war as pharmaceutical companies seek to curry the favor of insurers who have suffered sticker shock over Sovaldi’s thousand-dollar-a-day price.

AbbVie also plans to submit an application for the regimen to the European Union in May.

To read the press release, click here.

Search: New drug application, AbbVie, 3D, U.S. Food and Drug Administration, FDA, ABT-450, ombitasvir, ABT-267, dasabuvir, ABT-333, Scott Brun, Sovaldi, sofosbuvir, daclatasvir, asunaprevir, ledipasvir.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.